Cytotherapy

A time of editorial change: Vale et Salve!
pp. 391-393(3)
Author: Barrett J.

Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation
pp. 395-406(12)
Authors: Solomon S.; Tran T.; Carter C.; Donnelly S.; Hensel N.; Schindler J.; Bahceci E.; Ghetie V.; Michálek J.; Mavroudis D.; Read E.; Vitetta E.; Barrett A.

CML leukapheresis products can be enriched for CD34⁺ cells and simultaneously depleted of CD15⁺ cells using a simple Ab cocktail
pp. 407-413(7)
Authors: Richmond L.; Alcorn M.; Pearson C.; Cameron G.; Thomas T.; Eaves C.; Eaves A.; Holyoake T.

Meeting Report
pp. 415-418(4)
Authors: Stroncek D.; Harvath L.; Barrett J.

The basis of the alloimmune response
pp. 419-422(4)
Author: Barrett J.

B-cell immunity after allogeneic hematopoietic cell transplantation
pp. 423-424(2)
Author: Storek J.

The contribution of the thymus to immune reconstitution after hematopoietic stem-cell transplantation
pp. 425-426(2)
Author: Douek D.

Enhancing immune reconstitution after stem cell transplants with cytokines
pp. 427-428(2)
Author: Mackall C.

Phase I clinical trial of donor T-helper Type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant
pp. 429-430(2)
Authors: Fowler D.; Hou J.; Foley J.; Hakim F.; Odom J.; Castro K.; Carter C.; Read E.; Gea-Banacloche J.; Kasten-Sportes C.; Kwak L.; Wilson W.; Levine B.; June C.; Gress R.; Bishop M.

Immunologic aspects of hematopoietic stem-cell transplantation
pp. 431-432(2)
Authors: O'Reilly R.

Immune therapy for EBV infections after hemopoietic stem-cell transplant
pp. 433-434(2)
Authors: Heslop H.; Bollard C.; Gottschalk S.; Kuehnle I.; Huls M.; Gee A.; Brenner M.; Rooney C.

Immunotherapy for CMV infection
pp. 435-436(2)
Author: Einsele H.

Immune therapy of AML
pp. 437-438(2)
Author: Molldrem J.

Immunotherapy in the B-cell lymphomas
pp. 439-440(2)
Author: Gribben J.

T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma
pp. 441-441(1)
Authors: Warren E.; Tykodi S.; Murata M.; Sandmaier B.; Storb R.; Jaffee E.; Childs R.; Thompson J.; Greenberg P.; Riddell S.

Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones
pp. 443-444(2)
Author: Jensen M.

Natural killer cells: biology and application in stem-cell transplantation
pp. 445-446(2)
Authors: Farag S.; Fehniger T.; Ruggeri L.; Velardi A.; Caligiuri M.

What a cell-processing laboratory can and can't do for cellular therapy
pp. 447-448(2)
Author: Gee A.

Adoptive immunotherapy, the Food and Drug Administration and you: a regulatory approach to donor lymphocytes
pp. 449-449(1)
Author: Lazarus E.

Adoptive immunotherapy — the Food and Drug Administration and you: a regulatory framework for manipulated cellular products
pp. 451-453(3)
Author: Keane-Moore M.